u/Ninjake68

Author argues ADTX is an asymmetric deep-value microcap: its wholly owned subsidiary Ignite Proteomics was assigned an implied valuation of roughly $150 million in a definitive agreement to make it an independent public company, so the market may be pricing the remaining assets (Pearsanta diagnostics, immune modulation programs, Evofem-related assets) at almost nothing. The stated catalysts are closing the Ignite transaction, additional partnerships, asset monetization, improved financing terms, Nasdaq compliance progress and commercial revenue growth, supported by newly appointed interim CEO Jeffrey Busch's commercialization focus. The main stated risk is that the bull case requires reducing dilution pressure, generating commercial revenue, maintaining access to capital and avoiding further setbacks — if management fails, the stock could continue to struggle.